These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8070316)

  • 1. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake.
    Lin JH; Chen IW; deLuna FA
    Drug Metab Dispos; 1994; 22(3):400-5. PubMed ID: 8070316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats.
    Lin JH; Chen IW; Deluna FA
    Drug Metab Dispos; 1993; 21(5):800-4. PubMed ID: 7902239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
    Lin JH; Chen IW; deLuna FA; Hichens M
    J Pharmacol Exp Ther; 1993 Nov; 267(2):670-5. PubMed ID: 8246140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals.
    Lin JH; Duggan DE; Chen IW; Ellsworth RL
    Drug Metab Dispos; 1991; 19(5):926-32. PubMed ID: 1686238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats.
    Lin JH; Chen IW; Duggan DE
    Drug Metab Dispos; 1992; 20(4):473-8. PubMed ID: 1356720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal handling of alendronate in rats. An uncharacterized renal transport system.
    Lin JH; Chen IW; Deluna FA; Hichens M
    Drug Metab Dispos; 1992; 20(4):608-13. PubMed ID: 1356743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and plasma protein binding of zoledronic acid.
    Weiss HM; Pfaar U; Schweitzer A; Wiegand H; Skerjanec A; Schran H
    Drug Metab Dispos; 2008 Oct; 36(10):2043-9. PubMed ID: 18625688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of alendronate: an overview.
    Lin JH; Russell G; Gertz B
    Int J Clin Pract Suppl; 1999 Apr; 101():18-26. PubMed ID: 12669737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of remoxipride in different species. Species differences in metabolism.
    Widman M; Nilsson LB; Bryske B; Lundström J
    Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.
    Klotz U; Antonin KH; Bieck PR
    J Pharmacol Exp Ther; 1976 Oct; 199(1):67-73. PubMed ID: 789856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
    Peter CP; Guy J; Shea M; Bagdon W; Kline WF; Hayes WC
    J Pharmacol Exp Ther; 1996 Jan; 276(1):271-6. PubMed ID: 8558442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum protein binding of a new oral cephalosporin, CL 284,635, in various species.
    Bialer M; Tonelli AP; Kantrowitz JD; Yacobi A
    Drug Metab Dispos; 1986; 14(1):132-6. PubMed ID: 2868857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.
    Pongchaidecha M; Daley-Yates PT
    Drug Metab Dispos; 1993; 21(1):100-4. PubMed ID: 8095201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma.
    Steinke W; Ahr HJ; Hirayama M
    Arzneimittelforschung; 1997 Aug; 47(8):939-48. PubMed ID: 9296280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
    Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
    Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs.
    Usui T; Watanabe T; Higuchi S
    Drug Metab Dispos; 1995 Nov; 23(11):1214-9. PubMed ID: 8591721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse.
    Löscher W
    J Pharmacol Exp Ther; 1978 Feb; 204(2):255-61. PubMed ID: 340640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enantioselective plasma protein binding of bimoclomol.
    Visy J; Fitos I; Mády G; Urge L; Krajcsi P; Simonyi M
    Chirality; 2002 Aug; 14(8):638-42. PubMed ID: 12125033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of abouthiouzine: a novel antihyperthyroid drug.
    Alkharfy KM; Khan RM; Al-Hadiya BM; Abou-Auda HS; Abou-Shaaban RR
    Biopharm Drug Dispos; 2007 Apr; 28(3):105-11. PubMed ID: 17230598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.